Brent Hatzis-Schoch
CIK: 0001637054
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BDTX
Black Diamond Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Hatzis-Schoch Brent
Hatzis-Schoch Brent (SEC CIK 0001637054) files insider reports with the SEC as Officer of Black Diamond Therapeutics, Inc. (BDTX).
Signal8 holds 2 ownership filings by Hatzis-Schoch Brent, all Form 4s, filed between Jan 31, 2025 and Jan 23, 2026. Those filings report 2 transactions, from Jan 30, 2025 to Jan 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hatzis-Schoch Brent's filings is in CAMBRIDGE, MA.
Recent filings by Hatzis-Schoch Brent
Other insiders filing for Black Diamond Therapeutics, Inc. (BDTX)
- Behbahani Ali, Director
- Raman Prakash, Director
- Kulkarni Samarth, Director
- Menzel Garry E, Director
- Dhingra Kapil, Director
- Campbell Shannon, Director